farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2022.127farmaec-700Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИPharmacotherapy of insomnia in childhoodФармакотерапия инсомнии в детском возрастеhttps://orcid.org/0000-0002-5809-1457ТадтаеваЗ. Г.TadtaevaZ. G.

Тадтаева Зара Григорьевна – д.м.н., профессор кафедры фармакологии с курсом клинической фармакологии и фармакоэкономики. РИНЦ SPIN-код: 6086-0169

ул. Литовская, д. 2, Санкт-Петербург 194100

Zara G. Tadtaeva – Dr. Med. Sc., Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 6086-0169

2 Litovskaya Str., Saint Petersburg 194100

Tadtaeva2003@mail.ruhttps://orcid.org/0000-0001-9679-632XГалустянА. Н.GalustyanA. N.

Галустян Анна Николаевна – к.м.н., доцент, заведующая кафедрой фармакологии с курсом клинической фармакологии и фармакоэкономики. РИНЦ SPIN-код: 3303-7650

ул. Литовская, д. 2, Санкт-Петербург 194100

Anna N. Galustyan – MD, PhD, Associate Professor, Chief of Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 3303-7650

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0000-0002-0432-7946РусановскийВ. В.RusanovskyV. V.

Русановский Владимир Васильевич – д.м.н., профессор кафедры фармакологии с курсом клинической фармакологии и фармакоэкономики. РИНЦ SPIN-код: 7010-4530

ул. Литовская, д. 2, Санкт-Петербург 194100

Vladimir V. Rusanovsky – Dr. Med. Sc., Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д.м.н., профессор, научный руководитель. WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812; РИНЦ SPIN-код: 6317-9833

ул. Вавилова, д. 44, корп. 2, Москва 119333

Olga A. Gromova – Dr. Med. Sc., Professor, Research Supervisor. WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812; RSCI SPIN-code: 6317-9833

44 corp. 2 Vavilov Str., Moscow 119333

https://orcid.org/0000-0002-1528-411XСардарянИ. С.SardaryanI. S.

Сардарян Иван Суренович – к.м.н., доцент кафедры фармакологии с курсом клинической фармакологии и фармакоэкономики. РИНЦ SPIN-код: 9522-9761

ул. Литовская, д. 2, Санкт-Петербург 194100

Ivan S. Sardaryan – MD, PhD, Associate Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 9522-9761

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0000-0002-6725-8036КривдинаМ. Ю.KrivdinaM. Yu.

Кривдина Марина Юрьевна – невролог психоневрологического отделения

ул. Литовская, д. 2, Санкт-Петербург 194100

Marina Yu. Krivdina – Neurologist, Psychoneurological Department

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0000-0002-0200-5097КурицынаН. А.KuritsynaN. A.

Курицына Наталия Андреевна – к.м.н., доцент кафедры фармакологии с курсом клинической фармакологии и фармакоэкономики. РИНЦ SPIN-код: 4361-7365

ул. Литовская, д. 2, Санкт-Петербург 194100

Natalia A. Kuritsyna – MD, PhD, Associate Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 4361-7365

2 Litovskaya Str., Saint Petersburg 194100

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский педиатрический медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSaint Petersburg Pediatric Medical UniversityRussian FederationФедеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Informatics and Management”, Russian Academy of SciencesRussian Federation202228072022152284293Copyright © Tadtaeva Z.G., Galustyan A.N., Rusanovsky V.V., Gromova O.A., Sardaryan I.S., Krivdina M.Y., Kuritsyna N.A., 20222022Тадтаева З.Г., Галустян А.Н., Русановский В.В., Громова О.А., Сардарян И.С., Кривдина М.Ю., Курицына Н.А.Tadtaeva Z.G., Galustyan A.N., Rusanovsky V.V., Gromova O.A., Sardaryan I.S., Krivdina M.Y., Kuritsyna N.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/700

Insomnia is the most common form of sleep disturbance in childhood. Sleep disorders and a decrease in its duration and quality lead to the development of cognitive disorders, change emotional and behavioral functions of the developing organism, and negatively affect medical and psychological aspects that require medical correction. The article provides an overview of current literature data on pharmacological approaches to insomnia therapy in childhood. The general principles of treatment and the use of various pharmacological groups of drugs are discussed. It is shown that pharmacotherapy of childhood insomnia should be carried out based on knowledge about the age characteristics of patients, efficacy, safety, analysis of pharmacodynamic and pharmacokinetic parameters of the drugs used. Drug therapy should be combined with cognitive behavioral techniques, including adherence to sleep patterns and hygiene.

Инсомния является наиболее распространенной формой нарушения сна в детском возрасте. Дисфункции сна, уменьшение его продолжительности и качества приводят к развитию когнитивных нарушений, изменяют эмоционально-поведенческие функции развивающегося организма, негативно влияют на медико-психологические аспекты, которые требуют медикаментозной коррекции. В статье представлен обзор современных литературных данных о фармакологических подходах к терапии инсомнии в детском возрасте. Рассматриваются общие принципы лечения и применение различных фармакологических групп препаратов. Показано, что фармакотерапия инсомнии в детском возрасте должна основываться на знаниях о возрастных особенностях пациентов, а также на анализе эффективности, безопасности, фармакодинамических и фармакокинетических параметров применяемых препаратов. Медикаментозную терапию необходимо сочетать с когнитивно-поведенческими методиками, включая соблюдение режима сна и гигиены.

Сонинсомниядетифармакотерапияповеденческая терапияSleepinsomniachildrenpharmacotherapybehavioral therapyReferencesПолуэктов М.Г. Нарушения сна в детском возрасте: причины и современная терапия. Эффективная фармакотерапия. 2012; 1: 32–9.Poluektov M.G. Sleep disorders in childhood: causes and modern therapy. Effektivnaya farmakoterapiya / Effective Pharmacotherapy. 2012; 1: 32–9 (in Russ.).Ivanenko A., McLaughlin Crabtree V., Gozal D. Sleep and depression in children and adolescents. Sleep Med Rev. 2005; 9 (2): 115–29. https://doi.org/10.1016/j.smrv.2004.09.006.Ivanenko A., McLaughlin Crabtree V., Gozal D. Sleep and depression in children and adolescents. Sleep Med Rev. 2005; 9 (2): 115–29. https://doi.org/10.1016/j.smrv.2004.09.006.Cappuccio F.P., Taggart F.M., Kandala N.B., et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008; 31 (5): 619–26. https://doi.org/10.1093/sleep/31.5.619.Cappuccio F.P., Taggart F.M., Kandala N.B., et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008; 31 (5): 619–26. https://doi.org/10.1093/sleep/31.5.619.Маркданте К., Клигман Р. Основы педиатрии по Нельсону. 8-е изд. М.: Эксмо; 2021: 848 с.Marcdante K., Kliegman R.M. Nelson еssentials of pediatrics. 8th ed. Elsevier; 2018.Maski K., Owens J.F. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management. Lancet Neurol. 2016; 15 (11): 1170–81. https://doi.org/10.1016/S1474-4422(16)30204-6.Maski K., Owens J.F. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management. Lancet Neurol. 2016; 15 (11): 1170–81. https://doi.org/10.1016/S1474-4422(16)30204-6.Классификация нарушений сна (российский вариант международной классификации нарушений сна). URL: https://rossleep.ru/metodicheskie-rekomendatsii/klassifikatsiya-narusheniy-sna/ (дата обращения 22.03.2022).International Classification of Sleep Disorders Third Edition. Available at: https://j2vjt3dnbra3ps7ll1clb4q2-wpengine.netdna-ssl.com/wpcontent/uploads/2019/05/ICSD3-TOC.pdf (accessed 22.03.2022).Харламов Д.А., Кременчугская М.Р., Трифонова О.А. Полисомнография в диагностике нарушений сна у детей. Российский вестник перинатологии и педиатрии. 2008; 53 (5): 52–8.Kharlamov D.A., Kremenchugskaya M.R., Trifonova O.E. Polysomnography in the sleep disorders diagnostics in children. Russian Bulletin of Perinatology and Pediatrics. 2008; 53 (5): 52–8 (in Russ.).Mindell J.A., Emslie G., Blumer J., et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006; 117 (6): e1223–32. https://doi.org/10.1542/peds.2005-1693.Mindell J.A., Emslie G., Blumer J., et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006; 117 (6): e1223–32. https://doi.org/10.1542/peds.2005-1693.Кельмансон И.А. Фармакотерапия расстройств сна в дошкольном и младшем школьном возрасте. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120 (9-2): 55–61. https://doi.org/10.17116/jnevro202012009255.Kelmanson I.A. Pharmacotherapy of sleep disturbances in pre-school and elementary school children. S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120 (9-2): 55–61 (in Russ.). https://doi.org/10.17116/jnevro202012009255.Корабельникова Е.А. Лечение и профилактика инсомний у детей раннего возраста. Российский психиатрический журнал. 2012; 3: 62–70.Korabelnikova E.A. Treatment and prevention of insomnia in infants and young children. Russian Journal of Psychiatry. 2012; 3: 62–70 (in Russ.).Nunes M.L., Cavalcante V. Clinical evaluation and treatment of insomnia in childhood. J Pediatr (Rio J). 2005; 81 (4): 277–86 (in Portuguese).Nunes M.L., Cavalcante V. Clinical evaluation and treatment of insomnia in childhood. J Pediatr (Rio J). 2005; 81 (4): 277–86 (in Portuguese).Owens J.A., Mindell J.A. Pediatric insomnia. Pediatr Clin North Am. 2011; 58 (3): 555–69. https://doi.org/10.1016/j.pcl.2011.03.011.Owens J.A., Mindell J.A. Pediatric insomnia. Pediatr Clin North Am. 2011; 58 (3): 555–69. https://doi.org/10.1016/j.pcl.2011.03.011.Meltzer L.J. Clinical management of behavioral insomnia of childhood: treatment of bedtime problems and night wakings in young children. Behav Sleep Med. 2010; 8 (3): 172–89. https://doi.org/10.1080/15402002.2010.487464.Meltzer L.J. Clinical management of behavioral insomnia of childhood: treatment of bedtime problems and night wakings in young children. Behav Sleep Med. 2010; 8 (3): 172–89. https://doi.org/10.1080/15402002.2010.487464.Ophof D., Slaats M.A., Boudewyns A. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018; 177 (5): 641–8. https://doi.org/10.1007/s00431-018-3116-z.Ophof D., Slaats M.A., Boudewyns A. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018; 177 (5): 641–8. https://doi.org/10.1007/s00431-018-3116-z.Kaczor M., Skalski M. Treatment of behavioral sleep problems in children and adolescents – literature review. Psychiatr Pol. 2016; 50(3): 571–84. https://doi.org/10.12740/PP/41294.Kaczor M., Skalski M. Treatment of behavioral sleep problems in children and adolescents – literature review. Psychiatr Pol. 2016; 50(3): 571–84. https://doi.org/10.12740/PP/41294.Morgenthaler T.I., Owens J., Alessi C., et al. Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006; 29 (10): 1277–81.Morgenthaler T.I., Owens J., Alessi C., et al. Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006; 29 (10): 1277–81.Пчелина П.В., Полуэктов М.Г. Как лечить инсомнию раннего детского возраста. Эффективная фармакотерапия. 2016; 19: 52–9.Pchelina P.V., Poluektov M.G. How to treat insomnia of early childhood. Effektivnaya farmakoterapiya / Effective Pharmacotherapy. 2016; 19: 52–9 (in Russ.).Ferber R. Solve your child's sleep problems. Touchstone; 2006: 4646 pp.Ferber R. Solve your child's sleep problems. Touchstone; 2006: 4646 pp.Левин Я.И., Ковров Г.В., Полуэктов М.Г. и др. Инсомния, современные диагностические и лечебные подходы. М.: Медпрактика; 2005: 116 с.Levin Ya.I., Kovrov G.V., Poluektov M.G., et al. Insomnia, modern diagnostic and therapeutic approaches. Мoscow: Medpraktika; 2005: 116 pp. (in Russ.).Galland B., Meredith-Jones K., Gray A., et al. Criteria for nap identification in infants and young children using 24-h actigraphy and agreement with parental diary. Sleep Med. 2016; 19: 85–92. https://doi.org/10.1016/j.sleep.2015.10.013.Galland B., Meredith-Jones K., Gray A., et al. Criteria for nap identification in infants and young children using 24-h actigraphy and agreement with parental diary. Sleep Med. 2016; 19: 85–92. https://doi.org/10.1016/j.sleep.2015.10.013.Pelayo R., Dubic M. Pediatric sleep pharmacology. Semin Pediatr Neurol. 2008; 15 (2): 79–90. https://doi.org/10.1016/j.spen.2008.03.004.Pelayo R., Dubic M. Pediatric sleep pharmacology. Semin Pediatr Neurol. 2008; 15 (2): 79–90. https://doi.org/10.1016/j.spen.2008.03.004.Owens J.F., Rosen C.L., Mindell J.A. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010; 11 (7): 692–700. https://doi.org/10.1016/j.sleep.2009.11.015.Owens J.F., Rosen C.L., Mindell J.A. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010; 11 (7): 692–700. https://doi.org/10.1016/j.sleep.2009.11.015.Relia S., Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. Med Sci (Basel). 2018; 6 (4): 95. https://doi.org/10.3390/medsci6040095.Relia S., Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. Med Sci (Basel). 2018; 6 (4): 95. https://doi.org/10.3390/medsci6040095.Стал С.М. Основы психофармакологии. Теория и практика. М.: ГЭОТАР-Медиа; 2020: 656 с.Stahl S.M. Stahl’s essential psychopharmacology. Neuroscientific basis and practical application. 4 th ed. Cambridge University Press; 2013: 626 pp.Walsh J.K., Krystal A.D., Amato D.A., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007; 30 (8): 959–68. https://doi.org/10.1093/sleep/30.8.959.Walsh J.K., Krystal A.D., Amato D.A., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007; 30 (8): 959–68. https://doi.org/10.1093/sleep/30.8.959.Liskow B., Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry. 2004; 43 (8): 927–8. https://doi.org/10.1097/01.chi.0000129219.66563.aa.Liskow B., Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry. 2004; 43 (8): 927–8. https://doi.org/10.1097/01.chi.0000129219.66563.aa.Owens J.A., Moturi S. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009; 18 (4): 1001–16. https://doi.org/10.1016/j.chc.2009.04.009.Owens J.A., Moturi S. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009; 18 (4): 1001–16. https://doi.org/10.1016/j.chc.2009.04.009.Hatta K., Kishi Y., Wada K., et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014; 71 (4): 397–403. https://doi.org/10.1001/jamapsychiatry.2013.3320.Hatta K., Kishi Y., Wada K., et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014; 71 (4): 397–403. https://doi.org/10.1001/jamapsychiatry.2013.3320.Kawabe K., Horiuchi F., Oka Y., et al. The melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorder. Case Rep Psychiatry. 2014; 2014: 561071. https://doi.org/10.1155/2014/561071.Kawabe K., Horiuchi F., Oka Y., et al. The melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorder. Case Rep Psychiatry. 2014; 2014: 561071. https://doi.org/10.1155/2014/561071.Яхно Н.Н. Отчет о клинической эффективности препарата «мелаксен» фирмы Unipharm-USA (США) при лечении инсомний. Лечащий врач. 1999; 10: 26–7.Yakhno N.N. Report on the clinical efficacy of the drug “melaxen’ by Unipharm-USA (USA) in the treatment of insomnia. Lechaschi Vrach. 1999; 10: 26–7 (in Russ.).Weber J., Siddiqui M.A., Wagstaff A.J., et al. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010; 24 (8): 713–20. https://doi.org/10.2165/11200810-000000000-00000.Weber J., Siddiqui M.A., Wagstaff A.J., et al. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010; 24 (8): 713–20. https://doi.org/10.2165/11200810-000000000-00000.Kawabe K., Horiuchi F., Ochi M., et al. Suvorexant for the treatment of insomnia in adolescents. J Child Adolesc Psychopharmacol. 2017; 27 (9): 792–5. https://doi.org/10.1089/cap.2016.0206.Kawabe K., Horiuchi F., Ochi M., et al. Suvorexant for the treatment of insomnia in adolescents. J Child Adolesc Psychopharmacol. 2017; 27 (9): 792–5. https://doi.org/10.1089/cap.2016.0206.Kishi T., Nomura I., Matsuda Y., et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020; 128: 68–74. https://doi.org/10.1016/j.jpsychires.2020.05.025.Kishi T., Nomura I., Matsuda Y., et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020; 128: 68–74. https://doi.org/10.1016/j.jpsychires.2020.05.025.Bendz L.M., Scates A.C. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2010; 44 (1): 185–91. https://doi.org/10.1345/aph.1M365.Bendz L.M., Scates A.C. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2010; 44 (1): 185–91. https://doi.org/10.1345/aph.1M365.Johnson K.P., Malow B.A. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol. 2008; 10 (5): 350–9. https://doi.org/10.1007/s11940-008-0038-5.Johnson K.P., Malow B.A. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol. 2008; 10 (5): 350–9. https://doi.org/10.1007/s11940-008-0038-5.Bruni O., Alonso-Alconada D., Besag F., et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015; 19 (2): 122–33. https://doi.org/10.1016/j.ejpn.2014.12.007.Bruni O., Alonso-Alconada D., Besag F., et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015; 19 (2): 122–33. https://doi.org/10.1016/j.ejpn.2014.12.007.Andersen I.M., Kaczmarska J., McGrew S.G., et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008; 23 (5): 482–5. https://doi.org/10.1177/0883073807309783.Andersen I.M., Kaczmarska J., McGrew S.G., et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008; 23 (5): 482–5. https://doi.org/10.1177/0883073807309783.Dujardin S., Pijpers A., Pevernagie D. Prescription drugs used in insomnia. Sleep Med Clin. 2018; 13 (2): 169–82. https://doi.org/10.1016/j.jsmc.2018.03.001.Dujardin S., Pijpers A., Pevernagie D. Prescription drugs used in insomnia. Sleep Med Clin. 2018; 13 (2): 169–82. https://doi.org/10.1016/j.jsmc.2018.03.001.Carr R., Wasdell M.B., Hamilton D., et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007; 43 (4): 351–9. https://doi.org/10.1111/j.1600-079X.2007.00485.x.Carr R., Wasdell M.B., Hamilton D., et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007; 43 (4): 351–9. https://doi.org/10.1111/j.1600-079X.2007.00485.x.Lin G.J., Huang S.H., Chen S.J., et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013; 14 (6): 11742–66. https://doi.org/10.3390/ijms140611742.Lin G.J., Huang S.H., Chen S.J., et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013; 14 (6): 11742–66. https://doi.org/10.3390/ijms140611742.Bannai M., Kawai N. New therapeutic strategy for aminoacid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012; 118 (2): 145–8. https://doi.org/10.1254/jphs.11r04fm.Bannai M., Kawai N. New therapeutic strategy for aminoacid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012; 118 (2): 145–8. https://doi.org/10.1254/jphs.11r04fm.Owens J.A., Babcock D., Blumer J., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005; 1 (1): 49–59. https://doi.org/10.5664/jcsm.26297.Owens J.A., Babcock D., Blumer J., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005; 1 (1): 49–59. https://doi.org/10.5664/jcsm.26297.Meolie A.L., Rosen C., Kristo D., et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005; 1 (2): 173–87.Meolie A.L., Rosen C., Kristo D., et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005; 1 (2): 173–87.Хачатрян Л.Г., Погорелова М.С., Геппе Н.А. и др. Проблемы нарушения сна у детей раннего возраста: вопросы диагностики и коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119 (7-2): 25–32. https://doi.org/10.17116/jnevro201911907225.Khachatrian L.G., Pogorelova M.S., Geppe N.A., et al. The problem of insomnia in infant/young children: issues of diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119 (7-2): 25–32 (in Russ.). https://doi.org/10.17116/jnevro201911907225.Чутко Л.С., Сурушкина С.Ю., Яковенко Е.А. и др. Исследование эффективности применения препарата киндинорм в лечении неврастении у детей дошкольного возраста. Педиатрия. Журнал им. Г.Н. Сперанского. 2016; 95 (3): 140–4.Chutko L.S., Surushkina S.Y., Yakovenko E.A., et al. Research of kindinorm drug effectiveness in neurasthenia treatment in preschool children. Journal “Pediatria” named after G.N. Speransky. 2016; 95 (3): 140–4 (in Russ.).Яковлева Е.Е., Тадтаева З.Г., Галустян А.Н., Сардарян И.С. Проблема off-label назначений в терапии неонатальных судорог. Вестник Смоленской государственной медицинской академии. 2021; 20 (3): 43–50. https://doi.org/10.37903/vsgma.2021.3.5.Iakovleva E.E., Tadtaeva Z.G., Galustyan A.N., Sardaryan I.S. The problem of off-label prescriptions in the treatment of neonatal seizures. Vestnik of the Smolensk State Medical Academy. 2021; 20 (3): 43–50 (in Russ.). https://doi.org/10.37903/vsgma.2021.3.5.Nguyen M., Tharani S., Rahmani M., Shapiro M. A review of the use of clonidine as a sleep aid in the child and adolescent population. Clin Pediatr (Phila). 2014; 53 (3): 211–6. https://doi.org/10.1177/0009922813502123.Nguyen M., Tharani S., Rahmani M., Shapiro M. A review of the use of clonidine as a sleep aid in the child and adolescent population. Clin Pediatr (Phila). 2014; 53 (3): 211–6. https://doi.org/10.1177/0009922813502123.Xue M., Brimacombe M., Chaaban J., et al. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol. 2008; 23 (1): 6–13. https://doi.org/10.1177/0883073807307102.Xue M., Brimacombe M., Chaaban J., et al. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol. 2008; 23 (1): 6–13. https://doi.org/10.1177/0883073807307102.Keshavan M.S., Prasad K.M., Montrose D.M., et al. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. J Clin Psychopharmacol. 2007; 27 (6): 703–5. https://doi.org/10.1097/jcp.0b013e31815a884d.Keshavan M.S., Prasad K.M., Montrose D.M., et al. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. J Clin Psychopharmacol. 2007; 27 (6): 703–5. https://doi.org/10.1097/jcp.0b013e31815a884d.Robinson A.A., Malow B.A. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013; 28 (12): 1618–21. https://doi.org/10.1177/0883073812463069.Robinson A.A., Malow B.A. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013; 28 (12): 1618–21. https://doi.org/10.1177/0883073812463069.

The authors declare that there are no conflicts of interest present.